Tag:

NICE

Latest Headlines

Latest Headlines

NICE to bypass drugmakers in search of data to support pricey drugs

The U.K.'s drug price watchdog, the National Institute for Health and Care Excellence, says that from now on, NICE will request clinical trial data directly from European regulatory authorities whenever it feels a company isn't providing adequate information to make sound coverage decisions, according to a statement.

NICE slaps unusual rules on Alexion's pricey Soliris after atypical cost review

Despite its well-publicized rejections of several high-priced cancer drugs, the U.K.'s National Institute for Health and Care Excellence has just recommended what's widely considered to be the most expensive drug in the world--Alexion's Soliris. 

Cost watchdogs bar Boehringer, Lilly's diabetes med Jardiance--for now

Just as Eli Lilly and Boehringer Ingelheim's new diabetes drug Jardiance hit store shelves in the U.S., cost-effectiveness watchdogs in the U.K. were considering whether to give it their blessing. The verdict as of Thursday morning? Nay.

U.K.'s cancer drugs fund gets £160M--and power to push for lower prices

The U.K. has a workaround for expensive cancer drugs that its cost-effectiveness gatekeepers don't approve: a special fund to pay for those therapies, provided doctors jump through the hoops required to gain access.

Mad at NICE's cancer drug rejections? Look to drugmakers, agency chief says

Political shilly-shallying about the cost of drugs has to end, the chief of the U.K.'s cost-effectiveness agency says. Government officials and politicians need to be up front with the public about one stark fact: The country's health service just can't afford every drug that can help patients.

Celgene's cost-sharing offer persuades NICE to about-face on Revlimid

Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.

Celgene cost-sharing deal sways NICE to greenlight new Revlimid use

Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.

NICE Zytiga snub is 'plainly illogical,' critic says

U.K.'s National Institute for Health and Care Excellence has delivered a blow to Johnson & Johnson's Zytiga in final draft guidance recommending against the prostate cancer pill as a treatment for prostate cancer before chemotherapy. And nobody seems very happy about it--including NICE itself.

Skeptical U.K. watchdogs decide to back Gilead's hep C star Sovaldi

As Gilead's multibillion-dollar sales figures show, insurers and government payers are covering the highly effective--but highly pricey--hep C treatment. Now, if NICE's latest coverage proposal goes through, the U.K.'s National Health Service will officially be one of them.

NICE says social values, along with cost, need to be factored into decisions

The U.K.'s National Institute for Health and Care Excellence wants to know what "societal values" should be considered, along with cost and efficiency, when making decisions. Now an appointed group of 30 people have given it that feedback, PMLive reports.